Interleukin-6 (IL-6) is a molecule that helps control inflammation, and its levels rise with age and higher body weight, contributing to chronic inflammation and age-related diseases. Although IL-6 also has important roles in metabolism and tissue repair, blocking its harmful effects without disrupting its beneficial ones has been challenging. Recent research discovered a specific IL-6 signaling pathway that activates enzymes called SRC family kinases (SFKs), and blocking this pathway can protect against tissue damage.

In this study, researchers tested a new drug, R159, that blocks this harmful IL-6/SFK pathway. They gave the drug to older mice on a high-fat diet, which normally causes widespread inflammation and aging-related problems. The treatment significantly reduced inflammation in fat and liver tissue and protected the mice from bone loss, joint damage, and declines in brain cell regeneration. R159 also prevented excessive weight gain and boosted physical activity. These results suggest that selectively blocking this IL-6 signaling branch may be a promising way to reduce chronic inflammation and multiple age-related health issues.